Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 14 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

29%

4 trials in Phase 3/4

Results Transparency

0%

0 of 11 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
9(64.3%)
Phase 3
4(28.6%)
Phase 2
1(7.1%)
14Total
Phase 1(9)
Phase 3(4)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (14)

Showing 14 of 14 trials
NCT05834868Phase 3Completed

Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 2 Diabetes

Role: lead

NCT07282054Phase 3Completed

Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes

Role: lead

NCT07257627Phase 1Completed

Comparative PK/PD of Single-Dose THDB0206 at Different Injection Sites

Role: lead

NCT07036601Phase 2Recruiting

Phase II Study of THDBH120 Injection in Overweight or Obese Subjects

Role: lead

NCT07020949Phase 1Completed

Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of THDBH120 in Chinese Patients With T2DM

Role: lead

NCT06951945Phase 1Completed

Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of THDBH120 in Chinese Patients With Obesity

Role: lead

NCT06744868Phase 1Completed

A Single- and Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of THDBH120 Injection in Healthy Subjects

Role: lead

NCT06559722Phase 3Not Yet Recruiting

A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes

Role: lead

NCT06449703Phase 1Recruiting

A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide in Healthy Chinese Subjects

Role: lead

NCT02491528Phase 3Completed

A Phase III Study of Insulin Aspart Injection to Evaluate the Efficacy and Safety

Role: lead

NCT06153329Phase 1Completed

A Trial to Evaluate the Pharmacokinetics and Pharmacodynamics of THDB0206 Injection in Healthy Chinese Subjects

Role: lead

NCT05373186Phase 1Completed

A Trial Investigating the Pharmacodynamics of BC Combo THDB0207 Compared With Humalog® Mix25 and Simultaneous Injections of Humalog® and Lantus® in Healthy Chinese Volunteers

Role: collaborator

NCT05373212Phase 1Completed

A Trial Investigating the Dose Linearity and Safety of BC Combo THDB0207 in Subjects With Type 2 Diabetes

Role: collaborator

NCT05373199Phase 1Completed

A Trial Comparing the Pharmacodynamics and Pharmacokinetics of BC Combo THDB0207 and Lantus® and Humalog® in Subjects With Type 1 Diabetes

Role: collaborator

All 14 trials loaded